Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
09/22/2022 - 07:00 AM
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022, at 10:00 a.m. ET in New York, NY.
A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com . An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat. About Decibel Therapeutics
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. For more information about Decibel Therapeutics, please visit www.decibeltx.com Twitter
Investor Contact: julie.seidel@sternir.com
Media Contact: Chris@tenbridgecommunications.com
DBTX Rankings
#620 Ranked by Stock Gains
DBTX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
About DBTX
decibel therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. hearing loss is the most prevalent form of sensory impairment. it is estimated that 50 million people in the u.s., and 360 million people worldwide, suffer from some type of hearing loss. hearing disorders affect people of all ages and can have a profound impact on quality of life. by combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, decibel is pioneering a comprehensive approach to defining and treating the underlying biological causes of hearing disorders, and developing a pipeline of breakthrough drugs targeted to specific indications and patients. founded by the world’s preeminent experts in inner ear biology and hearing disorders, decibel therapeutics was launched in 2015 by third rock ventures and sr one and is headquartered in boston, mass. for more inf
